A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about 20% of their body weight, whereas those on semaglutide ... the maker of Wegovy and Ozempic ...

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

And one clearly comes out on top. Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized weight loss. But, strangely, no one has compared the ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 ...